VedaBio
PrivateLast Round
Series A
Extension
Sep 23, 2025
Total Funding Raised
$65.13M
Company Overview
VedaBio operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series A Extension round in September 2025.
VedaBio is a biotechnology company that develops molecular diagnostics equipment using a CRISPR-based platform for rapid, amplification-free detection of multiple analytes.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Medical Devices, Precision Medicine
Business Model
B2B
Customer Profile
Hardware + Subscription, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
VedaBio Comparables
Compare VedaBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nanopath | 86% | |
| Prominex, Inc. | 84% | |
| OraSure Technologies Inc | 79% |
For institutional investors. Book with your work email.
VedaBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Sep 23, 2025 | ||||
| Series A | Oct 17, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
VedaBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OMX Ventures | Series A, Series A Extension |
| Kleinmuntz Associates | Series A, Series A Extension |
| Y Combinator | Accelerator |
| OMX Ventures | Series A, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 23, 2025
$40M round completed.
- Sep 23, 2025
Signed a strategic agreement with Siemens Healthineers.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 16, 2026
VedaBio, Inc. is developing CRISPR-powered diagnostic products for decentralized and point-of-need settings in California, with a platform designed to eliminate target amplification in molecular testing workflows.
- hiresSep 16, 2026
On Sep 16th '26, VedaBio, Inc. appoints Valerie Dixon as its first independent board director in California, adding her healthcare finance and transaction expertise as the company advances its CRISPR-based molecular diagnostic technology toward commercialization.
For institutional investors. Book with your work email.
VedaBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about VedaBio's valuation, stock price, and market status.
Is VedaBio a public or private company?
VedaBio is a private company.
What is the current stock price of VedaBio?
VedaBio is a private company, so its shares have no public market price. Caplight tracks VedaBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is VedaBio worth (valuation)?
Valuation information for VedaBio is not publicly available.
Can I buy VedaBio stock?
VedaBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was VedaBio's last funding round?
VedaBio's most recent funding round was Series A Extension on September 23, 2025.
Who are the main investors in VedaBio?
Key investors in VedaBio include OMX Ventures, OMX Ventures.
Will VedaBio IPO soon?
No public IPO plans have been announced for VedaBio.
How can I track VedaBio secondary market activity?
Caplight tracks bids, offers, and trades in VedaBio's shares on secondary markets.